Insider Trading May 11, 2026 07:10 PM

StoneX Group Director Executes Common Stock Sale Amidst Recent Financial Performance

Director Steven A. Kass disposes of over $246,000 in shares as StoneX trades near its yearly peak.

By Caleb Monroe SNEX

Steven A. Kass, a member of the Board of Directors for StoneX Group Inc. (NASDAQ: SNEX), has completed a sale of company common stock. The transaction, which took place on May 11, 2026, involved the disposal of 2,000 shares at an average price point of $123.2594 per share. This liquidation resulted in total proceeds of $246,518. Following this specific transaction, Mr. Kass retains a direct holding of 53,266 shares of StoneX Group common stock.The sale occurs at a time when SNEX is trading near its 52-week high of $125.42, having demonstrated a 106% return over the previous year. While the stock has seen significant upward movement, current analysis suggests that the equity may be overvalued in relation to its calculated Fair Value.

StoneX Group Director Executes Common Stock Sale Amidst Recent Financial Performance
SNEX

Key Points

  • Director Steven A. Kass sold 2,000 shares at an average of $123.2594 per share, totaling $246,518.
  • StoneX reported strong earnings per share of $2.07, beating the $1.34 forecast, despite a revenue miss of $829.1 million against a $1.33 billion projection.
  • The stock has achieved a 106% return over the past year and is currently trading near its 52-week high of $125.42.

Insider Transaction Details

On May 11, 2026, StoneX Group Inc. director Steven A. Kass executed a sale of common stock. The transaction involved 2,000 shares, which were sold at an average price of $123.2594 per share. In total, the value of the shares disposed of by Mr. Kass amounted to $246,518. This move leaves the director with a direct ownership stake of 53,266 shares in the company.


Contextual Market Position

The timing of this insider sale is notable as StoneX Group finds itself trading near its 52-week high, which stands at $125.42. Over the course of the last year, the stock has delivered a substantial return of 106%. However, valuation metrics indicate a potential discrepancy between current market pricing and intrinsic worth; specifically, analysis suggests the stock currently appears overvalued compared to its Fair Value.


Recent Fiscal Performance

The insider activity follows the release of StoneX Group's second quarter financial results for fiscal year 2026. The reported earnings provided a nuanced view of the company's recent performance:

  • Earnings Per Share (EPS): The company reported EPS of $2.07, a figure that significantly outperformed the anticipated $1.34.
  • Revenue: Total revenue for the quarter reached $829.1 million, which was below the projected amount of $1.33 billion.

While the earnings per share exceeded analyst expectations and indicated a robust financial standing, the shortfall in revenue relative to projections created a mixed financial narrative for the period. These results have drawn interest from various investment firms as they assess the company's ongoing market position and overall health.


Key Analysis Points

  • Executive Liquidity: The sale by a director represents a significant movement of personal capital, though the director maintains a substantial remaining stake of 53,266 shares.
  • Valuation Divergence: There is a visible tension between the stock's strong 106% annual return and current assessments that the price may exceed its fair value.
  • Mixed Financial Metrics: The disparity between high earnings per share ($2.07 vs $1.34 expected) and lower revenue ($829.1 million vs $1.33 billion expected) highlights complexity in the company's recent quarterly performance.

Risk Assessment

  • Revenue Shortfall Risk: The gap between projected revenue of $1.33 billion and actual revenue of $829.1 million indicates potential volatility or challenges in meeting top-line growth expectations.
  • Valuation Risk: With the stock trading near its 52-week high and appearing overvalued relative to fair value, there is a risk of price correction.

Risks

  • Revenue discrepancy: The company's actual revenue was significantly lower than the projected $1.33 billion.
  • Overvaluation risk: Current analysis suggests the stock is overvalued relative to its Fair Value despite recent gains.

More from Insider Trading

Edwards Lifesciences CEO Executes Multi-Million Dollar Share Sale via Pre-Set Trading Plan May 12, 2026 Covista CFO Executes $1.26 Million Stock Sale via Pre-Scheduled Trading Plan May 12, 2026 Covista Executive Executes Planned Share Sale Amidst Corporate Growth and Financial Restructuring May 12, 2026 Covista Executive Executes $1.22 Million Stock Sale Under Pre-Planned Trading Program May 12, 2026 Ameriprise Financial Director Executes Stock Sale Amid Strong Earnings Performance May 12, 2026